The Global Pril-series Intermediate Market was valued at US$ 1.3 billion in 2025 and is projected to reach US$ 2.04 billion by 2034, recording a CAGR of 5.78% during 2026–2034. The market is expanding as pharmaceutical manufacturers continue to require high-quality intermediates to produce Pril-series drugs, particularly angiotensin-converting enzyme (ACE)...
Deutsch
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek